ACR Annual Meeting: Exposure to industrial emissions of fine particles matter and sulfur dioxide are associated with the presence of anti-citrullinated protein antibodies, a characteristic biomarker for rheumatoid arthritis, according to a study presented at the annual meeting of the American College of Rheumatology in Atlanta on November 12.
ACR Annual Meeting: In patients with moderate to severe systemic lupus erythematosus, anifrolumab (AstraZeneca) was superior to placebo for overall disease activity, skin disease and oral corticosteroid tapering, among other efficacy endpoints, according to a study presented at the annual meeting of the American College of Rheumatology in Atlanta on November 12.
In rheumatoid arthritis patients who are in sustained remission and receiving conventional synthetic DMARDs, continued treatment with stable doses led to fewer disease activity flares and less frequent radiographic joint damage progression than tapered csDMARD treatment, shows a study.
John Sundy, MD, PhD, senior vice president of Inflammation and Respiratory Disease with Gilead Sciences, discusses the results of the 156-week analysis of filgotinib in RA patients.
Philip Mease, MD, Director of Rheumatology Research at the Swedish Rheumatology Research Group, discusses why he believes some rheumatologists are skeptical of JAK inhibitors and where they fit in current treatment algorithms.
Martin Bergman, MD, clinical associate professor of Medicine at Drexel University, discusses the results of a study examining prevalence of burnout among rheumatologists.
ACR Annual Meeting: Single intra-articular doses of UBX0101 of up to 4 mg were well-tolerated by patients with painful knee osteoarthritis, according to a study presented at the annual meeting of the American College of Rheumatology in Atlanta on November 12. The treatment is in development, but if it pans out, it may reduce the effects aging on arthitic joints.
ACR Annual Meeting: In a small study, patients with macrophage activation syndrome (MAS) receiving emapalumab (Gamifant, Sobi) achieved complete response, according to data presented at the annual meeting of the American College of Rheumatology in Atlanta on November 12.
ACR Annual Meeting: The use of methotrexate combined with or without the oral JAK inhibitor tofacitinib produced no clinically meaningful difference in 179 psoriatic arthritis patients from the OPAL Balance study, presented at ACR 2019 this week.
ACR Annual Meeting: Cannabis use among patients with rheumatic diseases has increased since 2014, and those who tried cannabis tended to have worse pain, disease activity, and symptoms and were taking more analgesics, according to a study presented at the annual meeting of the American College of Rheumatology in Atlanta on November 13.
Full 52-week results of the SPIRT-H2H trial were presented during the late breaking session at ACR 2019.
Brian LaMoreaux, MD, medical director with Horizon Therapeutics, discusses response to concurrent methotrexate and pegloticase use for treating uncontrolled gout.
Deodhar discusses the results of a study comparing the symptoms and treatment patterns in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis.
Philip Mease, MD, Director of Rheumatology Research at Swedish Rheumatology Research Group, reflects upon new data and discusses where he sees guselkumab fitting into a PsA patient's current treatment plan.
A new study from ACR 2019 found tocilizumab outperformed rituximab in rheumatoid arthritis patients with low B-cell levels.
ACR Annual Meeting: In patients with active psoriatic arthritis, who are biologic-naïve, guselkumab (Tremfya, Janssen) improved joint and skin symptoms, physical function, quality of life, and resolved enthesitis and dactylitis, according to a study presented at annual meeting of the American College of Rheumatology in Atlanta on November 12.
ACR Annual Meeting: Patients with calcium pyrophosphate deposition (CPPD) disease may be at an increased risk of major adverse cardiovascular events along with a higher mortality rate compared to those without the disease, according to a study presented at annual meeting of the American College of Rheumatology in Atlanta on November 12.
Daniel Clauw, MD, of the University of Michigan, discusses how the diagnosis of a rheumatic condition can impact the mental health of patients.
Jeffrey Curtis, MD, discusses how the Vectra test can be a useful tool for rheumatologists at ACR 2019.
An analysis of more than 7000 patients presented at ACR 2019 found there was no significant differences in safety or efficacy of biologic DMARDs based on the age of RA onset.
Elaine Husni, MD, discusses how she goes about choosing which therapy is most appropriate for a patient with psoriatic arthritis.
ACR Annual Meeting: A large proportion of patients with rheumatoid arthritis achieved remission with either active conventional therapy or with one of three different biologic therapies, certolizumab, abatacept and tocilizumab, after 24 weeks of treatment, according to a study presented at the annual meeting of the American College of Rheumatology in Atlanta on November 12.
ACR Annual Meeting: More than half of survey psoriatic arthritis patients say they have adopted complementary or alternative medicine strategies and most say they've experienced some benefit, researchers reported November 12 at the annual meeting of the American College of Rheumatology in Atlanta.
ACR Annual Meeting: Methotrexate should be continued in most patients with active rheumatoid arthritis when biologic or targeted synthetic therapy is initiated, EU researchers reported in a poster presentation on November 12 at the annual meeting of the American College of Rheumatology in Atlanta.
ACR Annual Meeting: Compared with seven other biologics and a phosphodiesterase-4 inhibitor, the anti-IL-12/23 biologic ustekinumab was associated with a generally lower risk of serious infection requiring hospitalization in psoriasis or psoriatic arthritis patients, researchers reported on November 12 at the American College of Rheumatology annual meeting in Atlanta.
ACR Annual Meeting: The anti-IL-6 agent olokizumab was safe and effective when added to methotrexate in patients with rheumatoid arthritis in a phase three randomized controlled trial, researchers reported on November 12 at the American College of Rheumatology annual meeting in Atlanta.
ACR Annual Meeting: Patients with early rheumatoid arthritis and serological biomarkers of a poor prognosis who initiated treatment with abatacept plus methotrexate, sustained remission across all arms of a 48-week dose de-escalation trial, though the full combination produced the best maintenance, researchers reported November 12 at the American College of Rheumatology annual meeting in Atlanta.
Daniel Clauw, MD, of the University of Michigan, discusses the impact public perception has had on pain management practices for patients with rheumatic diseases and chronic pain.
ACR Annual Meeting: Gout patients who are admitted to the hospital with worsening heart failure, go on to have gout attacks during hospitalization leading to longer hospital stays, researchers reported November 10 at the annual meeting of the American College of Rheumatology in Atlanta.
ACR Annual Meeting: Intravenous golimumab produced lasting improvements in health-related quality of life for psoriatic arthritis patient one year post treatment, researchers reported on November 11 at the American College of Rheumatology annual meeting in Atlanta.